Martin J. Driscoll

Martin J. Driscoll discloses dealings in 4 companies, chiefly F-star Therapeutics, Inc., Javelin Pharmaceuticals, Inc and MetaStat, Inc. Over a trading history stretching from 12 May 2006 to 20 November 2020, the count stands at 46 filings.

In open-market terms, that means 38 purchases worth €790k on one side and 1 sale worth €702 on the other. The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 4 share grants and 1 option exercise. So far in 2020, the count stands at no purchases and 1 sale.

The median purchase comes to €11k. Clusters matter here: 17 out of 26 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 4 purchases show a median change of +9.2%, with the price up in 75% of them. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 23 November 2020: an open-market sale of €702, in F-star Therapeutics, Inc. The last purchase on record was published on 14 November 2019, which is 2,536 days ago. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.